Treating Clostridioides difficile infection is complicated in patients coinfected with COVID-19. However, a new study suggests a significant benefit of fecal microbiota transplant (FMT) in these coinfected patients.
New public health perspectives on aspergillosis, sporotrichosis, histoplasmosis, and coccidioidomycosis.
There has been increasing interest in the association between neural tube defects, dolutegravir, and integrase inhibitors as a class since 4 cases were reported in 2018.
The vaccine is approved as a 3-dose series, which consists of a 0.5 mL intramuscular injection, administered at 2, 4, and 6 months of age.
Novel modes of delivery are imperative to improve HIV suppression and prevent transmission.
The FDA has granted QIDP and Fast Track Designations for the oral formulation of SCY-078 for the treatment of vulvovaginal candidiasis.
Alnylam Pharmaceuticals announces exclusive licensing agreement with Vir Biotechnology for the development and commercialization of RNA Interference therapeutics for infectious diseases.
To better support the use of critical antibiotics, the Centers for Medicare & Medicaid Services revised the rules governing reimbursement for qualifying antibiotic products. For these changes to succeed, hospital systems will need to make adjustments.
The FDA has finalized its guidance on how to synchronize development of antimicrobials and antimicrobial susceptibility test devices.
A shocking find on a CT scan leads to an unexpected diagnosis.
The Closing Plenary of IDWeek 2019 discussed the challenges of vaccination and the optimism that we may be on the path to eradicating some global infectious diseases.
Michael K. Gusmano, PhD, discusses the importance of maintaining ethical standards in research evaluating potential therapeutics and vaccines for COVID-19.
Clostridium difficile rates in stem cell transplant patients are approximately 9 times greater than in hospitalized patients, with rates about twice as high in allogeneic vs autologous transplants.
The CDC’s ACIP recommends newly FDA-approved Shingrix as the preferred vaccine for the prevention of shingles in individuals 50 years of age or older.
This article seeks to review newer ART agents, as well as those in later stages of drug development, for the treatment of HIV-1 infection.
The quick Pitt Bacteremia Score offers accuracy comparable to the original version's across multiple infections, and maintains ease of use.
As we await novel compounds from a relatively apathetic industry, we are resurrecting antibiotics of which we have an outdated understanding. and that carry the potential for substantial side effects: polymyxins.
The new single-tablet regimen provides a safe and effective treatment option for patients with HIV.
Two recently approved agents offer significant activity against these hard-to-treat conditions.
Erin K. McCreary, PharmD, BCPS, BCIDP; and Jason M. Pogue, PharmD, BCPS, BCIDP, provide an update of published literature on experimental treatments for COVID-19 from the past week.
Experts weigh in on what Congress is doing to tackle the threat of antibiotic resistance.
This In the Literature piece details a study evaluating the appropriateness of prescriptions in comparison to evidence-based guidelines and expert opinion.
Reports of serious consequences from severe streptococcal infections have caused fear among the general public, but is this fear warranted?